Biotechnology
Bio4t2 announces first patient infused with CAR-T targeting solid tumors
SAN DIEGO, Jan. 11, 2023 /PRNewswire/ -- Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors. The CAR-T (B4t2-001) was developed from Bio4t2's PrismCore™ platform. "This first...
2023-01-11 09:00
2197
MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval
GENEVA, Jan. 11, 2023 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel
sirolimus-eluting balloon, has received conditional FDA Investigational Device
Exemption (IDE) approval to initiate its pivotal clinical trial for the
treatment of coronaryde novo lesions.
2023-01-11 09:00
2617
Samsung Biologics receives the Terra Carta Seal in recognition of the company's commitment to creating a sustainable future
* Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal. * The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. * Designed b...
2023-01-11 08:01
2083
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-2) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes
ROCKVILLE, Md. and SUZHOU, China, Jan. 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-01-11 00:00
2906
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
TOKYO, Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' ant...
2023-01-10 21:05
2211
Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
ROSCREA, Ireland, Jan. 10, 2023 /PRNewswire/ – Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal ("GI") disorders, is pleased to announce opening of the Investigational New Drug ...
2023-01-10 21:00
2366
EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™
PROVIDENCE, R.I., Jan. 10, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2. The n...
2023-01-10 21:00
3197
Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER+/HER2- Breast Cancer
NEW YORK, Jan. 10, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase (TTK, also known as Mps...
2023-01-10 21:00
2221
Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023
SAN FRANCISCO, Jan. 10, 2023 /PRNewswire/ -- Complete Genomics Inc (
https://completegenomics.mgiamericas.com/
2023-01-10 20:30
2569
Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations
SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for sunvozertinib for the treatment of advanced NSCLC with EGFR exon20ins...
2023-01-10 17:03
1877
FAPON to attend 41st Annual J.P. Morgan Healthcare Conference
SHENZHEN, China, Jan. 10, 2023 /PRNewswire/ -- FAPON, a leading life sciences company, today announces that its senior executive management will attend the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jielun ZHU, CFO & CIO of FAPON, will be making a corporate presentation o...
2023-01-10 16:37
1739
General Biologicals Corporation (GBC) and Chairman Lin Tsong-Chin Honored at Asia Pacific Enterprise Awards 2022 Taiwan
SINGAPORE, Jan. 9, 2023 /PRNewswire/ -- The Asia Pacific Enterprise Awards (APEA) 2022 Taiwan is pleased to honor 34 outstanding business leaders and enterprises for their commendable dedication toward spearheadingTaiwan's economic recovery and development. Presented by leading regional NGO En...
2023-01-10 09:54
1715
Lydus Medical Announces FDA Clearance of Vesseal™, The Microvascular Anastomosis Aid Device for Small Arteries
RA'ANANA, Israel, Jan. 10, 2023 /PRNewswire/ -- Lydus Medical
2023-01-10 09:00
1739
SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night'
SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse into the future of its global business in new drug, CDMO, biotech SK Biopharmaceuticals joins SK Inc.'s Bio Investment Center, SK pharmteco, or 'SK bio family,'for potential investment, partnerships...
2023-01-10 07:00
1672
SK Inc. hosts "SK Bio Night" in San Francisco to expand global partnerships
* SK to spark innovative ideas and identify new business opportunities by presenting its global strategy and growth roadmap to over 50 partners * Newly appointed executives to lead SK's biopharmaceutical businesses to attend the event * SK Inc. to promote the competitiveness of K-bio and pro...
2023-01-10 07:00
1478
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tre...
2023-01-09 23:25
1896
Shanton Screens First Subjects in Phase 2b Refractory/Tophaceous Gout Study with SAP-001
SAP-001 is an oral once-a-day investigational gout product with Best-in-Class potential for acute and chronic use in uncontrolled patients BRIDGEWATER, N.J., Jan. 9, 2023 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and top...
2023-01-09 22:00
2156
Mars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
* The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care * Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future generati...
2023-01-09 21:15
2147
SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia
* The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) * SK biosciences plans to launch the zoster vaccine with proven efficacy and safety starting in Southeast Asian market SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -...
2023-01-09 21:00
1990
SoniVie Raises $60m in Round C Financing, and Appoints New Board Members
The funds, provided by new investors and current shareholder, will be used to
support the Company clinical and regulatory path towards pre-market approval of
its TIVUS™ technology for the treatment of hypertension
TEL AVIV, Israel, Jan. 9, 2023 /PRNewswire/ -- SoniVie Ltd.
2023-01-09 20:00
2292
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 281 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 278 media titles]
2024-04-18 14:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 276 media titles]
2024-04-19 13:25
Most Read
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3817
Allianz Partners Introduces Instant Online Chat for HCF Travel Insurance Customers
2024-04-15 08:00
3083
Goldpac Exhibits at InnoEx 2024
2024-04-13 10:00
3003
